I'll bet you've made this mistake. And I'll also bet that your kids... and grandkids... are making it right now. I've seen it time and time again. It's one of the quickest ways to lose money in the market. Just as an example, let's say you put a few hundred buc
Stocks are starting the month of September on a positive note after the jobs report for August provided another bullish catalyst for traders. While the broader market indices were able to beat the seasonality trends in August with slight gains, the fact is that stocks continue to trade with lower correlations. This means that picking the right stocks is becoming increasingly important.
Ambarella (NASDAQ:AMBA) is primarily known for supplying image processing SoCs (system on chips) for GoPro’s (NASDAQ:GPRO) action cameras. As a result, Ambarella’s stock often rose and fell with GoPro’s in the past.
But over the past few quarters, Ambarella reduced its dependence on GoPro while increasing its presence in adjacent markets. That’s why Ambarella’s....More>>>
It all started with a fifth-grade class project. Scott Tarde, CEO of George G. Glenner Alzheimer’s Family Centers, which has operated dementia day care facilities in California’s San Diego county for 35 years, was amazed at his 12-year-old daughter’s enthusiasm over her Junior Achievement “BizTown” field trip.
Welcome to another edition of “3 Things in Biotech You Should Learn Today.” Yours truly is currently mired in post-ASCO craziness, with lots of news finally coalescing and being interpreted. Like did you know that in colorectal cancer it looks like we might be attacking with chemotherapy too aggressively? There were all kinds of major updates there that we will be mulling for years.
Longtime readers know Steve Sjuggerud is a true contrarian… Steve has made a career of recommending cheap, hated assets that most investors have no interest in owning… And he has a long track record of winners to show for it (including the best-performing recommendation in Stansberry Research history). But in last month's issue of his True Wealth Systems service,....More>>>
Gainers Loxo Oncology Inc (NASDAQ: LOXO) rose 32.7 percent to $65.00 in pre-market trading after the company reported that larotrectinib trial demonstrated 76 percent confirmed objective response rate. Dynavax Technologies Corporation (NASDAQ: DVAX) shares rose 22 percent to $7.20 in the pre-market trading session after the company on Friday presented updated data for SD-101 in combination....More>>>
Dear Evan Hansen of铿cially opened at the Music Box Theater on Dec. 4, moving to Broadway after a hugely successful run at the Second Stage Theater in New York earlier this year. With an impressive creative team, a bold, original new story and a wave of good buzz behind it, Dear Evan Hansen may become the next Broadway sensation and the season’s breakout hit.
Our Long Idea reports aim to identify those firms that the market has overlooked and that, when analyzed beyond standard metrics, are significantly undervalued. These hidden gems provide excellent upside potential to any portfolio, with little downside risk.
In addition to individual Long Ideas, we provide Model Portfolios that provide well-screened lists of companies based on specific criteria....More>>>
Alphabet (GOOGL) doesn't seem like your typical growth stock, considering it opened at $1,030.99 this morning (Oct. 27, 2017). But Wall Street is overlooking the explosive potential our tech guru sees…
Money Morning Director of Technology & Venture Capital Research
On November 1, 2017, Allergan (NYSE: AGN) reported better-than-expected Q3 2017 results, fueled by a solid performance from the key growth drivers and management rebased down the expectations for 2018 EPS assuming a worst case scenario for Restasis.
Since Under Armour (UAA) is down over 75% from its highs, this stock has attracted many bargain hunters at Seeking Alpha who've been trying to determine if it's worth jumping into. This is my 15th Under Armour article and I've not once recommended the stock (and I still don't). There have been ~
Beating Alzheimers is going to be a team sport. We now have our new quarterback. Referencing billionaire Microsoft co-founder Bill Gates announcement today to join the fight to cure Alzheimers, George Vradenburg, chairman, president and co-founder of UsAgainstAlzheimers - a movement bent on stop
Sales Trends A Bit Soft, But Nothing To Worry About
I have been a bit disappointed by Nordstroms (NYSE:JWN) recent results. Not because it was a bad quarter per se, but because it broke the sequence of constant overperformance compared to other peers in the